US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by AN2 Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Announces $40 Million Private Placement Financing
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
News headline image
AN2 Therapeutics to Participate at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
Tickers ANTX
< Previous 1 2 Next >